It looks like Motely Fool has ran an article on CRNT. It's relieving that someone else agrees with me. Here is what Motely Fool concludes:
"At its price of about $6.50 per share, Ceragon is trading at only 15.9 times its 2007 diluted GAAP earnings per share. Company management expects net income to increase at a rate even higher than sales in 2008, so assuming that GAAP earnings grow by 30%, Ceragon's forward multiple is an attractive 12.2. Even though dilution from a share offering late last year will eat into EPS somewhat, Ceragon is still priced at a steep discount to its projected growth."
The article also gives a possible cause or two for the recent sell out, but comes down on the side that I originally did. There's no relevant reason that the stock should be down this much.
I'm tempted to set my sell order at $16 (a double) and not worry about it. I still think $16 or more is coming this year.




